| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (NCT02382549) | Craig L Slingluff, Jr | 2016-04-01 |
| Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors (NCT02836795) | Shanghai Junshi Bioscience Co., Ltd. | 2016-04-01 |
| Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma (NCT02696356) | BrightPath Biotherapeutics | 2016-04-01 |
| A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c (NCT03048253) | OrienGene Biotechnology Ltd. | 2016-03-29 |
| Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases (NCT02739386) | Bristol-Myers Squibb | 2016-02-29 |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors (NCT02573259) | Pfizer | 2016-02-10 |
| Holistic Needs Assessments in Patients With Melanoma (NCT06189261) | University of Surrey | 2016-02-01 |
| Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers (NCT02639026) | Abramson Cancer Center at Penn Medicine | 2016-01-26 |
| Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors (NCT02646748) | Incyte Corporation | 2016-01-25 |
| Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (NCT02607813) | Novartis Pharmaceuticals | 2016-01-18 |
| Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma (NCT02694965) | Duke University | 2016-01-01 |
| A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients (NCT02671513) | Jiangsu HengRui Medicine Co., Ltd. | 2016-01-01 |
| Prospective Melanoma Database (NCT02884362) | Institut Claudius Regaud | 2016-01-01 |
| Biomarker-driven Therapy for Melanoma (NCT05063058) | Charite University, Berlin, Germany | 2016-01-01 |
| A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours (NCT02586987) | AstraZeneca | 2015-12-28 |
| Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (NCT02599402) | Bristol-Myers Squibb | 2015-12-20 |
| Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) (NCT02565992) | Viralytics | 2015-12-17 |
| Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (NCT02403778) | University of Colorado, Denver | 2015-12-17 |
| A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (NCT02621021) | National Cancer Institute (NCI) | 2015-12-04 |
| Study of Trametinib and Nab-paclitaxel in Patients With Melanoma (NCT02300935) | SCRI Development Innovations, LLC | 2015-12-01 |
| Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma (NCT02452281) | Rabih Said | 2015-12-01 |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (NCT02568267) | Hoffmann-La Roche | 2015-11-19 |
| Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas (NCT02602756) | Centre Antoine Lacassagne | 2015-11-02 |
| Collaborative Network to Take Responsibility for Oral Anticancer Therapy (NCT02861209) | KU Leuven | 2015-11-01 |
| A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (NCT02498665) | Sumitomo Pharma America, Inc. | 2015-11-01 |
| A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine (NCT02545075) | Bristol-Myers Squibb | 2015-10-31 |
| Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study (NCT02780089) | Bristol-Myers Squibb | 2015-10-23 |
| A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors (NCT02516527) | Bristol-Myers Squibb | 2015-10-16 |
| Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy (NCT02581228) | Optimata Ltd. | 2015-10-01 |
| Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma (NCT02574533) | Gradalis, Inc. | 2015-10-01 |
| Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma (NCT02650492) | Clinical Laserthermia Systems AB | 2015-10-01 |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer (NCT02543645) | Celldex Therapeutics | 2015-10-01 |
| Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response (NCT02439008) | Centre Oscar Lambret | 2015-09-16 |
| Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance (NCT02385253) | Northwestern University | 2015-09-15 |
| Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) (NCT02553642) | Memorial Sloan Kettering Cancer Center | 2015-09-14 |
| myDC/pDC in Stage III Melanoma Patients (NCT02574377) | Radboud University Medical Center | 2015-09-01 |
| Safety Study of MGD009 in B7-H3-expressing Tumors (NCT02628535) | MacroGenics | 2015-09-01 |
| Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma (NCT02717364) | Bristol-Myers Squibb | 2015-08-27 |
| Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) (NCT02437136) | Syndax Pharmaceuticals | 2015-08-26 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases (NCT02036086) | Sunnybrook Health Sciences Centre | 2015-08-01 |
| Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID) (NCT02470273) | Rockefeller University | 2015-08-01 |
| A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping (NCT02509598) | Cardinal Health 414, LLC | 2015-08-01 |
| Cytokine-induced Killer Study for Patients With Stage II Melanoma (NCT02498756) | The First People's Hospital of Changzhou | 2015-08-01 |
| Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma (NCT02427893) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-08-01 |
| Melanomas Excised in Primary Care vs Secondary Care Excision (NCT03169036) | University of Aberdeen | 2015-07-31 |
| Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) (NCT02362594) | Merck Sharp & Dohme LLC | 2015-07-16 |
| Intratumoral Injections of LL37 for Melanoma (NCT02225366) | M.D. Anderson Cancer Center | 2015-07-08 |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors (NCT02452424) | Daiichi Sankyo | 2015-07-02 |
| Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab (NCT02600169) | University Medical Center Groningen | 2015-07-01 |
| A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence (NCT02334735) | Nina Bhardwaj | 2015-07-01 |
| Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes (NCT02416336) | Oncovision Inc | 2015-07-01 |
| Application of Genomic Techniques and Image Processing Using Artificial Intelligence to Obtain a Predictor Model Risk of Melanoma (NCT02511119) | Maimónides Biomedical Research Institute of Córdoba | 2015-07-01 |
| Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer (NCT02475213) | MacroGenics | 2015-07-01 |
| Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (NCT02583516) | Grupo Español Multidisciplinar de Melanoma | 2015-06-30 |
| Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy (NCT03438279) | Bristol-Myers Squibb | 2015-06-23 |
| fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth (NCT02613325) | Washington University School of Medicine | 2015-06-08 |
| Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery (NCT02527304) | Albert Einstein College of Medicine | 2015-06-01 |
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma (NCT02425306) | Craig L Slingluff, Jr | 2015-05-12 |
| Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) (NCT02307149) | Viralytics | 2015-05-05 |
| Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques (NCT02393001) | University of Florida | 2015-05-01 |
| A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy (NCT02431572) | Massachusetts General Hospital | 2015-05-01 |
| Melanoma Perception and Health Literacy in People of Color (NCT02437305) | Northwestern University | 2015-05-01 |
| Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma (NCT02451488) | Mayo Clinic | 2015-05-01 |
| Study of the CD40 Agonistic Monoclonal Antibody APX005M (NCT02482168) | Apexigen America, Inc. | 2015-05-01 |
| Phase I/II Study of PDR001 in Patients With Advanced Malignancies (NCT02404441) | Novartis Pharmaceuticals | 2015-04-27 |
| Safety Study of AMG 228 to Treat Solid Tumors (NCT02437916) | Amgen | 2015-04-21 |
| A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain (NCT02308020) | Eli Lilly and Company | 2015-04-20 |
| Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833 (NCT02437227) | Royal Marsden NHS Foundation Trust | 2015-04-15 |
| Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology (NCT03797053) | Assistance Publique - Hôpitaux de Paris | 2015-04-06 |
| T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies (NCT02457650) | Shenzhen Second People's Hospital | 2015-04-01 |
| Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies (NCT02724488) | University Health Network, Toronto | 2015-04-01 |
| Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC (NCT02407171) | Yale University | 2015-04-01 |
| A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (NCT02385669) | Craig L Slingluff, Jr | 2015-04-01 |
| Moletest Clinical Study in Scotland (NCT02196246) | Moletest Scotland Ltd | 2015-03-27 |
| Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer (NCT02381314) | MacroGenics | 2015-03-26 |
| A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) (NCT02332668) | Merck Sharp & Dohme LLC | 2015-03-19 |
| Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (NCT02388906) | Bristol-Myers Squibb | 2015-03-16 |
| Longitudinal Study of Behavioral Changes, Economic and Sociological After CAncer (NCT02893774) | Institut Cancerologie de l'Ouest | 2015-03-12 |
| Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b (NCT02339324) | Yana Najjar | 2015-03-06 |
| An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (NCT02320058) | Bristol-Myers Squibb | 2015-03-05 |
| Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography (NCT02335476) | National Taiwan University Hospital | 2015-03-01 |
| Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma (NCT02406183) | Radiotherapie | 2015-03-01 |
| In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® (NCT02423863) | Oncovir, Inc. | 2015-03-01 |
| Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (NCT02410733) | BioNTech SE | 2015-03-01 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Digital vs. Printed Photographs: Impact on Skin Self-Examinations (NCT02520622) | University of Pennsylvania | 2015-02-16 |
| Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) (NCT02346955) | Famewave Ltd. | 2015-02-01 |
| Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes (NCT02870244) | Loyola University | 2015-02-01 |
| Quality of Life and Surgical Late Effects of Melanoma Treatment (NCT02352623) | Herlev Hospital | 2015-02-01 |
| Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy (NCT02501551) | Yonsei University | 2015-02-01 |
| Phase IIB TL + YCWP + DC in Melanoma (NCT02301611) | Elios Therapeutics, LLC | 2015-01-01 |
| Circulating Tumor DNA Exposure in Peripheral Blood (NCT03517332) | Quantgene Inc. | 2015-01-01 |
| Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (NCT02306850) | St. Louis University | 2015-01-01 |
| A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma (NCT02110355) | Kartos Therapeutics, Inc. | 2014-12-19 |
| Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (NCT02263508) | Amgen | 2014-12-08 |
| Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy (NCT02307500) | Istituto Clinico Humanitas | 2014-12-01 |
| Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma (NCT01531244) | Washington University School of Medicine | 2014-12-01 |
| A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) (NCT02327078) | Incyte Corporation | 2014-11-26 |
| Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases (NCT02374242) | Melanoma Institute Australia | 2014-11-04 |